News

Besins Healthcare has launched in the UK its new treatment, based on progesterone, to prevent miscarriage.

Prometrium is designed for use by women experiencing early pregnancy bleeding and those with a history of recurrent miscarriage and in clinical trials demonstrated a significant improvement in live birth rates.

Irina Spirieva, general manager of Besins Healthcare UK & Ireland, said: “We are committed to working alongside the NHS and HCPs to improve access, awareness and outcomes for women facing the uncertainty of early pregnancy complications.”

The launch follows the success of the PRISM trial, which assessed the impact of progesterone therapy on women with early pregnancy complications. The study found that women who received progesterone were significantly more likely to carry their pregnancies to term. Among women with three or more previous miscarriages, the risk of miscarriage dropped by 28%, and live birth rates rose to 72%, compared to 57% in the placebo group.

The launch of Prometrium adds to the company’s range of hormonal therapies, which also target menopause, endometriosis, reproductive health and testosterone deficiency.